Fundamental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) granules in the pediatric field

Y. Sato, S. Iwata, H. Akita

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fundamental and clinical studies have been performed on BRL 25000 (clavulanic acid 1 part-amoxicillin 2 parts) granules in the pediatric field. The antibacterical activities of BRL 25000 and amoxicillin (AMPC) were investigated against clinically isolated and laboratory stocked strains. BRL 25000 was superior to AMPC against strains of E. coli, Salmonella sp. and Klebsiella sp., and similar against Gram-positive cocci. Serum concentrations of AMPC and clavulanic acid (CVA) were measured 0.25, 0.5, 1, 2, 4 and 6 hours after administration of BRL 25000 granules at dose levels 7.5, 10, 15 and 20 mg/kg. At 7.5 mg/kg peak level of AMPC of 2.69 μg/ml was achieved about 2 hours after dosing with a biological half-life of 1.64 hours; the corresponding value for CVA was 0.53 μg/ml at 1 hour with a T 1/2 of 1.46 hours. At 10 mg/kg, AMPC also peak after 2 hours (3.82 μg/ml) and the T 1/2 was 1.63 hours, whilst for CVA the value was 0.56 μg/ml with a T 1/2 of 1.24 hours. The value for AMPC at 15 mg/kg was 5.18 μg/ml at 1 hour post dose with a T 1/2 of 1.48 hours, and for CVA 4.01 μg/ml at 1 hour with a T 1/2 of 0.89 hour. At the highest dose of 20 mg/kg, the AMPC level reached 4.21 μg/ml after 2 hours with a T 1/2 of 2.39 hours, and the CVA peak was 1.64 μg/ml at 1 hour with a T 1/2 of 1.01 hours. The 6 hour urinary recovery of AMPC and CVA following administration of the BRL 25000 granules ranged from 38 ~ 64% and 2 ~ 33%, respectively. In clinical studies, the BRL 25000 granules were administered to 15 cases with pediatric infections and the clinical response was excellent or good in all cases treated (100%). Bacteriological investigation was performed on 13 strains from 12 cases and all strains were eradicated (100%). Regarding side effects, elevation of eosinophil was observed in 1 case and vomiting in 3 cases.

Original languageEnglish
Pages (from-to)327-341
Number of pages15
JournalJapanese Journal of Antibiotics
Volume38
Issue number2
Publication statusPublished - 1985

Fingerprint

Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acid
Pediatrics
Amoxicillin
Gram-Positive Cocci
Klebsiella
Clinical Studies
Eosinophils
Salmonella
Vomiting
Half-Life
Escherichia coli
Infection
Serum

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Fundamental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) granules in the pediatric field. / Sato, Y.; Iwata, S.; Akita, H.

In: Japanese Journal of Antibiotics, Vol. 38, No. 2, 1985, p. 327-341.

Research output: Contribution to journalArticle

@article{055f9d05e66e46da8c5dfa34440ba4f6,
title = "Fundamental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) granules in the pediatric field",
abstract = "Fundamental and clinical studies have been performed on BRL 25000 (clavulanic acid 1 part-amoxicillin 2 parts) granules in the pediatric field. The antibacterical activities of BRL 25000 and amoxicillin (AMPC) were investigated against clinically isolated and laboratory stocked strains. BRL 25000 was superior to AMPC against strains of E. coli, Salmonella sp. and Klebsiella sp., and similar against Gram-positive cocci. Serum concentrations of AMPC and clavulanic acid (CVA) were measured 0.25, 0.5, 1, 2, 4 and 6 hours after administration of BRL 25000 granules at dose levels 7.5, 10, 15 and 20 mg/kg. At 7.5 mg/kg peak level of AMPC of 2.69 μg/ml was achieved about 2 hours after dosing with a biological half-life of 1.64 hours; the corresponding value for CVA was 0.53 μg/ml at 1 hour with a T 1/2 of 1.46 hours. At 10 mg/kg, AMPC also peak after 2 hours (3.82 μg/ml) and the T 1/2 was 1.63 hours, whilst for CVA the value was 0.56 μg/ml with a T 1/2 of 1.24 hours. The value for AMPC at 15 mg/kg was 5.18 μg/ml at 1 hour post dose with a T 1/2 of 1.48 hours, and for CVA 4.01 μg/ml at 1 hour with a T 1/2 of 0.89 hour. At the highest dose of 20 mg/kg, the AMPC level reached 4.21 μg/ml after 2 hours with a T 1/2 of 2.39 hours, and the CVA peak was 1.64 μg/ml at 1 hour with a T 1/2 of 1.01 hours. The 6 hour urinary recovery of AMPC and CVA following administration of the BRL 25000 granules ranged from 38 ~ 64{\%} and 2 ~ 33{\%}, respectively. In clinical studies, the BRL 25000 granules were administered to 15 cases with pediatric infections and the clinical response was excellent or good in all cases treated (100{\%}). Bacteriological investigation was performed on 13 strains from 12 cases and all strains were eradicated (100{\%}). Regarding side effects, elevation of eosinophil was observed in 1 case and vomiting in 3 cases.",
author = "Y. Sato and S. Iwata and H. Akita",
year = "1985",
language = "English",
volume = "38",
pages = "327--341",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "2",

}

TY - JOUR

T1 - Fundamental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) granules in the pediatric field

AU - Sato, Y.

AU - Iwata, S.

AU - Akita, H.

PY - 1985

Y1 - 1985

N2 - Fundamental and clinical studies have been performed on BRL 25000 (clavulanic acid 1 part-amoxicillin 2 parts) granules in the pediatric field. The antibacterical activities of BRL 25000 and amoxicillin (AMPC) were investigated against clinically isolated and laboratory stocked strains. BRL 25000 was superior to AMPC against strains of E. coli, Salmonella sp. and Klebsiella sp., and similar against Gram-positive cocci. Serum concentrations of AMPC and clavulanic acid (CVA) were measured 0.25, 0.5, 1, 2, 4 and 6 hours after administration of BRL 25000 granules at dose levels 7.5, 10, 15 and 20 mg/kg. At 7.5 mg/kg peak level of AMPC of 2.69 μg/ml was achieved about 2 hours after dosing with a biological half-life of 1.64 hours; the corresponding value for CVA was 0.53 μg/ml at 1 hour with a T 1/2 of 1.46 hours. At 10 mg/kg, AMPC also peak after 2 hours (3.82 μg/ml) and the T 1/2 was 1.63 hours, whilst for CVA the value was 0.56 μg/ml with a T 1/2 of 1.24 hours. The value for AMPC at 15 mg/kg was 5.18 μg/ml at 1 hour post dose with a T 1/2 of 1.48 hours, and for CVA 4.01 μg/ml at 1 hour with a T 1/2 of 0.89 hour. At the highest dose of 20 mg/kg, the AMPC level reached 4.21 μg/ml after 2 hours with a T 1/2 of 2.39 hours, and the CVA peak was 1.64 μg/ml at 1 hour with a T 1/2 of 1.01 hours. The 6 hour urinary recovery of AMPC and CVA following administration of the BRL 25000 granules ranged from 38 ~ 64% and 2 ~ 33%, respectively. In clinical studies, the BRL 25000 granules were administered to 15 cases with pediatric infections and the clinical response was excellent or good in all cases treated (100%). Bacteriological investigation was performed on 13 strains from 12 cases and all strains were eradicated (100%). Regarding side effects, elevation of eosinophil was observed in 1 case and vomiting in 3 cases.

AB - Fundamental and clinical studies have been performed on BRL 25000 (clavulanic acid 1 part-amoxicillin 2 parts) granules in the pediatric field. The antibacterical activities of BRL 25000 and amoxicillin (AMPC) were investigated against clinically isolated and laboratory stocked strains. BRL 25000 was superior to AMPC against strains of E. coli, Salmonella sp. and Klebsiella sp., and similar against Gram-positive cocci. Serum concentrations of AMPC and clavulanic acid (CVA) were measured 0.25, 0.5, 1, 2, 4 and 6 hours after administration of BRL 25000 granules at dose levels 7.5, 10, 15 and 20 mg/kg. At 7.5 mg/kg peak level of AMPC of 2.69 μg/ml was achieved about 2 hours after dosing with a biological half-life of 1.64 hours; the corresponding value for CVA was 0.53 μg/ml at 1 hour with a T 1/2 of 1.46 hours. At 10 mg/kg, AMPC also peak after 2 hours (3.82 μg/ml) and the T 1/2 was 1.63 hours, whilst for CVA the value was 0.56 μg/ml with a T 1/2 of 1.24 hours. The value for AMPC at 15 mg/kg was 5.18 μg/ml at 1 hour post dose with a T 1/2 of 1.48 hours, and for CVA 4.01 μg/ml at 1 hour with a T 1/2 of 0.89 hour. At the highest dose of 20 mg/kg, the AMPC level reached 4.21 μg/ml after 2 hours with a T 1/2 of 2.39 hours, and the CVA peak was 1.64 μg/ml at 1 hour with a T 1/2 of 1.01 hours. The 6 hour urinary recovery of AMPC and CVA following administration of the BRL 25000 granules ranged from 38 ~ 64% and 2 ~ 33%, respectively. In clinical studies, the BRL 25000 granules were administered to 15 cases with pediatric infections and the clinical response was excellent or good in all cases treated (100%). Bacteriological investigation was performed on 13 strains from 12 cases and all strains were eradicated (100%). Regarding side effects, elevation of eosinophil was observed in 1 case and vomiting in 3 cases.

UR - http://www.scopus.com/inward/record.url?scp=0021895508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021895508&partnerID=8YFLogxK

M3 - Article

C2 - 3847521

AN - SCOPUS:0021895508

VL - 38

SP - 327

EP - 341

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 2

ER -